Annovis Bio, Inc. (ANVS) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Annovis Bio, Inc. on September 29, 2025, covering events occurring on September 25, 2025. The Company is a Delaware corporation trading on the New York Stock Exchange under the symbol ANVS and is classified as an emerging growth company.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on corporate governance and executive compensation.
Material Changes
The primary material change reported is the appointment of Mark Guerin as Chief Financial Officer, effective September 25, 2025. Mr. Guerin, age 57, previously served as CFO of Onconova Therapeutics (now Traws Pharma, Inc.) from 2016 through February 2025. He holds a bachelor's degree in accounting and possesses CPA, CMA, and CFM certifications.
Compensatory Arrangements and Outlook
In connection with his appointment, Mr. Guerin's compensation package includes:
- Annual base salary of $450,000.
- Annual target bonus of 40% of base salary.
- Stock options to purchase 200,000 shares of common stock.
- Six months of severance pay.
- Participation in standard employee benefit plans.
The filing states there are no transactions required to be disclosed under Item 404(a) of Regulation S-K between the Company and Mr. Guerin. No specific guidance, risks, or contingencies regarding financial outlook were disclosed in this specific filing.
Investor Verification Checklist
- Verify the vesting schedule and exercise price for the 200,000 stock options granted to the new CFO.
- Review the full text of the press release (Exhibit 99.1) for additional strategic context regarding the leadership change.
- Confirm the Company's current cash runway and burn rate in the most recent 10-Q or 10-K, as this 8-K does not contain liquidity data.
- Monitor future filings for any changes to the Company's financial reporting standards given its emerging growth company status.